Published in Cancer Weekly, January 28th, 2003
Salt Lake-based Myriad Genetics holds both a U.S. and Canadian patent on the use of the BRAC1 and BRAC2 genetic sequence in diagnostic cancer screening tests. Mutations of those genes significantly increase an individual's chance of developing inherited forms of breast or ovarian cancer.
On January 6, 2003, Ontario Health Minister Tony Clement said his government would ignore Myriad's patent and move ahead with blood screening to detect the presence of the mutation.
He said honoring the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.